Alliancebernstein L.P. Raises Stake in BioSpecifics Technologies Corp (NASDAQ:BSTC)

Alliancebernstein L.P. boosted its stake in BioSpecifics Technologies Corp (NASDAQ:BSTC) by 401.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,820 shares of the biopharmaceutical company’s stock after buying an additional 32,685 shares during the period. Alliancebernstein L.P. owned approximately 0.57% of BioSpecifics Technologies Corp worth $2,237,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Chicago Equity Partners LLC increased its position in BioSpecifics Technologies Corp by 37.3% in the first quarter. Chicago Equity Partners LLC now owns 13,115 shares of the biopharmaceutical company’s stock worth $719,000 after buying an additional 3,565 shares during the period. Wedge Capital Management L L P NC bought a new position in BioSpecifics Technologies Corp during the first quarter worth $2,093,000. Geneva Advisors LLC increased its position in BioSpecifics Technologies Corp by 2.1% in the first quarter. Geneva Advisors LLC now owns 14,406 shares of the biopharmaceutical company’s stock worth $789,000 after buying an additional 293 shares during the period. Adams Diversified Equity Fund Inc. increased its position in BioSpecifics Technologies Corp by 2.8% in the first quarter. Adams Diversified Equity Fund Inc. now owns 14,900 shares of the biopharmaceutical company’s stock worth $817,000 after buying an additional 400 shares during the period. Finally, Russell Investments Group Ltd. increased its position in BioSpecifics Technologies Corp by 13.8% in the first quarter. Russell Investments Group Ltd. now owns 34,451 shares of the biopharmaceutical company’s stock worth $1,887,000 after buying an additional 4,171 shares during the period. 55.74% of the stock is currently owned by hedge funds and other institutional investors.

BioSpecifics Technologies Corp (BSTC) opened at 51.10 on Monday. BioSpecifics Technologies Corp has a 1-year low of $35.79 and a 1-year high of $58.79. The stock has a 50 day moving average price of $50.79 and a 200-day moving average price of $52.71. The firm has a market cap of $366.44 million, a P/E ratio of 31.35 and a beta of 1.76.

TRADEMARK VIOLATION NOTICE: This piece was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.themarketsdaily.com/2017/07/17/alliancebernstein-l-p-raises-stake-in-biospecifics-technologies-corp-nasdaqbstc.html.

Separately, Zacks Investment Research downgraded BioSpecifics Technologies Corp from a “hold” rating to a “sell” rating in a research note on Monday, May 15th.

About BioSpecifics Technologies Corp

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Institutional Ownership by Quarter for BioSpecifics Technologies Corp (NASDAQ:BSTC)

Receive News & Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply